Business Context and Reporting Period
Company: NERVGEN PHARMA CORP.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Date of Filing: June 1, 2026
Principal Executive Office: Vancouver, British Columbia, Canada
This filing serves as a notification of a Material Change Report (Exhibit 99.1) dated June 1, 2026. The document incorporates this report by reference into the company's Registration Statements on Form F-10 and Form S-8.
Key Financial Metrics
The provided filing text does not contain specific financial data. No values are disclosed for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing explicitly references a "Material Change Report" dated June 1, 2026, as Exhibit 99.1. However, the text of the Form 6-K itself does not describe the specific nature or details of this material change.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, specific risks, contingencies, or details regarding unusual items. The document functions primarily as a cover sheet to incorporate the referenced Material Change Report.
Investor Verification Checklist
- Review Exhibit 99.1 (Material Change Report) to understand the specific event triggering this filing.
- Verify the status of the Registration Statements on Form F-10 (File No. 333-296217) and Form S-8 (File Nos. 333-292927 and 333-295632) to which this report is incorporated.
- Confirm if the material change impacts the company's capital structure, operations, or regulatory standing.